|
|
Construction of eukaryotic expression vector
of human arresten gene and its secreted expression in HEK 293 cells |
Wei LI PhD 1, Siming GUAN MM 1, Zifang SONG PhD 2, Qichang ZHENG PhD 2, Jun XIONG PhD 2, Dan SHANG PhD 2, Xiaogang SHU PhD 2, |
1.Department of Gerontology,
Union Hospital, Tongji Medical College, Huazhong University of Science
and Technology, Wuhan 430022, China; 2.Department of General
Surgery, Union Hospital, Tongji Medical College, Huazhong University
of Science and Technology, Wuhan 430022, China; |
|
|
Abstract The eukaryotic expression vector of human arresten gene was constructed and its secretive expression human embryonic kidney (HEK 293) cells was detected. Human arresten gene was amplified from recombinant plasmid pGEM-Arr by polymerase chain reaction (PCR), and then digested with restriction endonucleases BamH I and EcoR I. The target fragment was inserted into the BamH I and EcoR I restriction sites of eukaryotic expression vector pSecTag2 to construct pST-AT. Restriction analysis and DNA sequencing indicated that the arresten gene was successfully inserted into pSecTag2. The recombinant plasmid was subsequently transfected into HEK 293 cells with LipofectAMINETM2000 Reagent, and the expression of the target gene was detected. RT-PCR revealed that the mRNA of the target gene was transcribed in the transfected HEK 293 cells. Western Blot analysis verified that the recombinant protein in supernatants was correct. The supernatants of transfected cells were prepared, and 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay was carried out to assess their effect on the proliferation of human umbilical vein endothelial cells, which showed that the recombinant protein could significantly suppress the proliferation of human umbilical vein endothelial cells in vitro. These results provided a solid foundation to explore the usage of arresten in tumor anti-angiogenic gene therapy.
|
Keywords
angiogenesis inhibitor
arresten
eukaryotic expression
HEK 293 cells
endothelial cells
|
Issue Date: 05 September 2009
|
|
|
Carmeliet P, Jain R K. Angiogenesis in cancer andother diseases. Nature, 2000, 407(6801): 249―257
doi: 10.1038/35025220
|
|
Abe R. Angiogenesisin tumor growth and metastasis. Curr PharmDes, 2008, 14(36): 3779
doi: 10.2174/138161208786898671
|
|
Hayden E C. Cutting off cancer’s supply lines. Nature, 2009, 458(7239): 686―687
doi: 10.1038/458686b
|
|
Folkman J. Angiogenesisin cancer, vascular, rheumatoid and other disease. Nat Med, 1995, 1(1): 27―31
doi: 10.1038/nm0195-27
|
|
Mysliwiec P, Pawlak K, Bandurski R, Kedra B. Soluble angiogenesismarkers in gastric tumor patients. FoliaHistochem Cytobiol, 2009, 47(1): 81―86
|
|
Chamberlain M C. Antiangiogenesis: biology and utility in the treatment of gliomas. Expert Rev Neurother, 2008, 8(10): 1419―1423
doi: 10.1586/14737175.8.10.1419
|
|
Kerbel R S. Tumor angiogenesis: past, present and the near future. Carcinogenesis, 2000, 21(3): 505―515
doi: 10.1093/carcin/21.3.505
|
|
Grandis J R, Argiris A. Targeting angiogenesis frompremalignancy to metastases. Cancer PrevRes (Phila Pa), 2009, 2(4): 291―294
doi: 10.1158/1940-6207.CAPR-09-0032
|
|
Bergers G, Javaherian K, Lo K M, Folkman J, Hanahan D. Effects of angiogenesis inhibitorson multistage carcinogenesis in mice. Science, 1999, 281(5415): 808―812
doi: 10.1126/science.284.5415.808
|
|
Kesisis G, Broxterman H, Giaccone G. Angiogenesis inhibitors. Drug selectivity and targetspecificity. Curr Pharm Des, 2007, 13(27): 2795―2809
doi: 10.2174/138161207781757033
|
|
Shannon A M, Williams K J. Antiangiogenics and radiotherapy. J Pharm Pharmacol, 2008, 60(8): 1029―1036
doi: 10.1211/jpp.60.8.0009
|
|
Cao Y. Molecularmechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res, 2008, 100: 113―131
doi: 10.1016/S0065-230X(08)00004-3
|
|
Shah V H, Bruix J. Antiangiogenic therapy: notjust for cancer anymore? Hepatology, 2009, 49(4): 1066―1068
doi: 10.1002/hep.22872
|
|
Browder T, Butterfield C E, Kräling B M, Shi B, Marshall B, O’Reilly M S, Folkman J. Antiangiogenicscheduling of chemotherapy improves efficacy against experimentaldrug-resistant cancer. Cancer Res, 2000, 60(7): 1878―1886
|
|
Sudhakar A, Nyberg P, Keshamouni V G, Mannam A P, Li J, Sugimoto H, Cosgrove D, Kalluri R. Human alpha1 type IV collagenNC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1integrin. J Clin Invest, 2005, 115(10): 2801―2810
doi: 10.1172/JCI24813
|
|
Pasco S, Brassart B, Ramont L, Maquart F X, Monboisse J C. Control of melanoma cellinvasion by type IV collagen. Cancer DetectPrev, 2005, 29(3): 260―266
doi: 10.1016/j.cdp.2004.09.003
|
|
Nyberg P, Xie L, Sugimoto H, Colorado P, Sund M, Holthaus K, Sudhakar A, Salo T, Kalluri R. Characterization of the anti-angiogenic properties ofarresten, an alpha1beta1 integrin-dependent collagen-derived tumorsuppressor. Exp Cell Res, 2008, 314(18): 3292―3305
doi: 10.1016/j.yexcr.2008.08.011
|
|
Mundel T M, Kalluri R. Type IV collagen-derivedangiogenesis inhibitors. Microvasc Res, 2007, 74(2,3): 85―89
|
|
Colorado P C, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K, Volk R, Zamborsky E D, Herman S, Sarkar P K, Ericksen M B, Dhanabal M, Simons M, Post M, Kufe D W, Weichselbaum R R, Sukhatme V P, Kalluri R. Anti-angiogenic cues from vascular basement membranecollagen. Cancer Res, 2000, 60(9): 2520―2526
|
|
Ademuyiwa F O, Miller K D. Incorporation of antiangiogenictherapies in the treatment of metastatic breast cancer. Clin Breast Cancer, 2008, 8 Suppl 4: S151―S156
doi: 10.3816/CBC.2008.s.011
|
|
Fujita Y, Abe R, Shimizu H. Clinical approaches toward tumor angiogenesis: past,present and future. Curr Pharm Des, 2008, 14(36): 3820―3834
doi: 10.2174/138161208786898680
|
|
Song Z, Zheng Q , Li W, Xiong J, Shang D, Shu X. Molecularcloning and sequencing of human arresten gene. Zhonghua Shiyan Waike Zazhi, 2002, 19(1): 46,47 (in Chinese)
|
|
Song Z, Zheng Q, Zhu L, Hu A, Li Y, Shu X, Tian Y. Construction of prokaryoticexpression vector of human angiogenesis inhibitor arresten and itsexpression in E. coli. Zhongguo BinglishengliZazhi, 2003, 19(9): 1161―1164 (in Chinese)
|
|
Taraboletti G, Giavazzi R. Modelling approaches forangiogenesis. Eur J Cancer, 2004, 40(6): 881―889
doi: 10.1016/j.ejca.2004.01.002
|
|
Harper J, Moses M A. Molecular regulation of tumorangiogenesis: mechanisms and therapeutic implications. EXS, 2006, 96: 223―268
doi: 10.1007/3-7643-7378-4_10
|
|
Ruegg C, Mutter N. Anti-angiogenic therapiesin cancer: achievements and open questions. Bull Cancer, 2007, 94(9): 753―762
|
|
Rayson D, Vantyghem S A, Chambers A F. Angiogenesis as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia, 1999, 4(4): 415―423
doi: 10.1023/A:1018774618873
|
|
Rosenblatt M I, Azar D T. Anti-angiogenic therapy:Prospects for treatment of ocular tumors. Semin Ophthalmol, 2006, 21(3): 151―160
doi: 10.1080/08820530500350787
|
|
Song Z, Zheng Q, Shu X, Zhu L, Hu A, Li Y. Cloningand expression of human arresten gene and effect of its recombinantprotein on endothelial cell proliferation. Zhonghua Shiyan Waike Zazhi, 2005, 22(5): 616―617 (in Chinese)
|
|
Sacchetti A, Cappetti V, Marra P, Dell’Arciprete R, El Sewedy T, Crescenzi C, Alberti S. Greenfluorescent protein variants fold differentially in prokaryotic andeukaryotic cells. J Cell Biochem, 2001, 36 Suppl: 117―128
doi: 10.1002/jcb.1091
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|